Diagnostic pathways to wild‐type transthyretin amyloid cardiomyopathy: a multicentre network study
暂无分享,去创建一个
C. Mazzoni | C. Autore | M. Emdin | A. Foli | P. Milani | C. Rapezzi | M. Cameli | G. Limongelli | L. Crotti | F. Guerra | G. Sinagra | S. Perlini | E. Merli | R. Mussinelli | P. Vianello | L. Obici | M. Merlo | G. Palladini | F. Perfetto | M. Zampieri | F. Cappelli | C. Gagliardi | S. Longhi | E. Biagini | M. Canepa | E. Gardini | G. Mandoli | F. Fabris | B. Musumeci | S. Carigi | G. Tini | L. De Michieli | A. Aimo | G. Vergaro | A. Cipriani | A. Argirò | V. Rella | G. Palmiero | F. Marzo | G. Ciliberti | M. Serenelli | E. Monti | I. Porto | G. Ricci Lucchi | A. Caponetti | G. Saturi | G. Fabbri | G. Varrà | Eugenio Sessarego | Domitilla Russo | M. Bartolotti | G. G. Varrà
[1] L. Lund,et al. Temporal Trends of Heart Failure Hospitalizations in Cardiology Versus Noncardiology Wards According to Ejection Fraction: 16-Year Data From the SwedeHF Registry , 2022, Circulation. Heart failure.
[2] M. Benson,et al. Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis , 2022, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[3] J. Smith,et al. Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries , 2022, ESC heart failure.
[4] M. Emdin,et al. Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta‐analysis of screening studies , 2022, European journal of heart failure.
[5] G. Parati,et al. Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC‐TIVE study, an Italian nationwide survey , 2022, European journal of heart failure.
[6] F. Rutten,et al. Evaluation of the cardiac amyloidosis clinical pathway implementation: a real-world experience , 2022, European heart journal open.
[7] Sanjiv J. Shah,et al. Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey , 2021, JACC. CardioOncology.
[8] P. de Paepe,et al. Trends in diagnosis, referral, red flag onset, patient profiles and natural outcome of de novo cardiac amyloidosis and their multidisciplinary implications , 2021, Acta cardiologica.
[9] C. Autore,et al. Yield of bone scintigraphy screening for transthyretin‐related cardiac amyloidosis in different conditions: Methodological issues and clinical implications , 2021, European journal of clinical investigation.
[10] C. Di Mario,et al. Early Diagnosis and Outcome in Patients With Wild-Type Transthyretin Cardiac Amyloidosis. , 2021, Mayo Clinic proceedings.
[11] N. Fine,et al. Prevalence and Prognostic Significance of Frailty Among Patients With Transthyretin Amyloidosis Cardiomyopathy. , 2021, Circulation. Heart failure.
[12] A. Masri,et al. Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review , 2021, Cardiology and Therapy.
[13] C. Di Mario,et al. Changes in the perceived epidemiology of amyloidosis: 20 year-experience from a Tertiary Referral Centre in Tuscany. , 2021, International journal of cardiology.
[14] U. Eriksson,et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases , 2021, European journal of heart failure.
[15] A. Masri,et al. Recipe for Success in Transthyretin Cardiomyopathy: Monoclonal Protein Rule Out, SPECT Imaging, and Genetic Testing. , 2020, JACC. Cardiovascular imaging.
[16] E. Ashley,et al. Temporal Trend of Age at Diagnosis in Hypertrophic Cardiomyopathy , 2020, Circulation. Heart failure.
[17] P. Cintas,et al. Gateway and journey of patients with cardiac amyloidosis , 2020, ESC heart failure.
[18] I. Porto,et al. Characteristics of current heart failure patients admitted to internal medicine vs. cardiology hospital units: the VASCO study , 2020, Internal and Emergency Medicine.
[19] Sanjiv J. Shah,et al. Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy , 2020, Circulation.
[20] G. Parati,et al. Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. , 2020, International journal of cardiology.
[21] G. Felker,et al. Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy , 2019, JACC. CardioOncology.
[22] C. Rapezzi,et al. Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. , 2019, Circulation. Heart failure.
[23] A. Petrie,et al. Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. , 2019, Circulation.
[24] Paul A. Harris,et al. The REDCap consortium: Building an international community of software platform partners , 2019, J. Biomed. Informatics.
[25] F. Dominici,et al. Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States. , 2019, Circulation. Heart failure.
[26] Sanjiv J. Shah,et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy , 2018, The New England journal of medicine.
[27] R. Falk,et al. ‘A new staging system for cardiac transthyretin amyloidosis’: is it already on the verge of obsolescence? , 2018, European heart journal.
[28] C. Rapezzi,et al. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths , 2017, European heart journal.
[29] James C Moon,et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis , 2016, Circulation.